Canada Markets close in 2 hrs 3 mins

Talaris Therapeutics, Inc. (TALS)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
2.6900-0.2100 (-7.24%)
As of 01:55PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous Close2.9000
Open2.8000
Bid2.6600 x 800
Ask2.6700 x 900
Day's Range2.6000 - 2.8325
52 Week Range2.0400 - 17.4850
Volume310,494
Avg. Volume142,851
Market Cap114.337M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-1.9530
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est23.25
  • GlobeNewswire

    Talaris Therapeutics Provides FREEDOM-1 Phase 3 Clinical Update

    Figure 1 HLA Mismatch of FREEDOM-1 Subjects (n=7) Figure 2 Time since kidney transplant All three FREEDOM-1 patients treated with FCR001 who are more than 12 months post-transplant have been successfully weaned off chronic anti-rejection drugs All FREEDOM-1 patients who received FCR001 at least three months prior to the data cutoff date have achieved and maintained >50% T-cell chimerism, a potential biomarker predictive of achieving tolerance Conference call scheduled for today at 8:00 a.m. ET B

  • GlobeNewswire

    Talaris Therapeutics Presents Additional Phase 2 Data and Analyses at American Transplant Congress 2022

    Real-world, retrospective analysis of Phase 2 patients versus matched controls finds FCR001-treated patients have improved kidney function and fewer cardiometabolic complications than patients on immunosuppression after 5 years In long-term follow up of Phase 2 patients, all patients originally weaned off IS have continued to remain off IS without rejecting their donated kidney Update on FREEDOM-1 study originally planned for June 8 now rescheduled to June 30 BOSTON and LOUISVILLE, Ky., June 07,

  • GlobeNewswire

    Talaris Therapeutics Announces Conference Call to Highlight Presentations at the American Transplant Congress (ATC) and Provide a Data Update from its Phase 3 FREEDOM-1 Study

    BOSTON and LOUISVILLE, Ky., June 01, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune and blood disorders, today announced it will host a conference call to discuss its presentations at the American Transplant Congress (ATC) and provide a data update from its ongoing Phase 3 FREEDOM-1 study in living donor kidney